- TRADE NAME: Xadago (Newron)
- INDICATIONS: Adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing 'off' episodes
- CLASS: Monoamine oxidase B inhibitor
- HALF-LIFE: 20–26 hours
- FDA APPROVAL DATE: 03/21/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Cyclobenzaprine, Dextromethorphan, Dopaminergic antagonists, Imatinib, Irinotecan, Isoniazid, Lapatinib, Linezolid, Meperidine, Methadone, Methylphenidate, Metoclopramide, Mitoxantrone, Other MAO inhibitors, Propoxyphene, Rosuvastatin, Serotonergic drugs, St John's Wort, Sulfasalazine, Sympathomimetics, Topotecan, Tramadol, Tricyclic or tetracyclic antidepressants, Viloxazine
Please login to view the rest of this drug profile.
Page last updated 04/15/2024
